Assessing Mitochondrial Protein Synthesis in Drug Toxicity Screening

Drug-Induced Mitochondrial Dysfunction

Volumn , Issue , 2008, Pages 463-472

  Mckee, Edward E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drugs and mitochondrial protein synthesis; Mitochondrial isolation and respiratory control ratio; Mitochondrial protein synthesis assessment

Indexed keywords

EID: 65549130074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470372531.ch19     Document Type: Chapter

References (40)

1. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell . New York: Garland Science; 2002.
2. Chomyn A, Cleeter MW, Ragan CI, Riley M, Doolittle RF, Attardi G. URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. Science. 1986;234:614-618.
3. Brien T. Properties of human mitochondrial ribosomes. IUBMB Life. 2003; 55:505-513.
4. Spremulli LL, Coursey A, Navratil T, Hunter SE. Initiation and elongation factors in mammalian mitochondrial protein biosynthesis. Prog Nucleic Acid Res Mol Biol. 2004;77:211-261.
5. Zhang L, Ging NC, Komoda T, Hanada T, Suzuki T, Watanabe K. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 2005;579:6423-6427.
6. Mears JA, Sharma MR, Gutell RR, et al. A structural model for the large subunit of the mammalian mitochondrial ribosome. J Mol Biol. 2006;358:193-212.
7. Bottger EC. Antimicrobial agents targeting the ribosome: the issue of selectivity and toxicity-lessons to be learned. Cell Mol Life Sci. 2007;64:791-795.
8. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med. 1989; 87:44N-48N.
9. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 2006;50:2042-2049.
10. Feder HM, Jr. Chloramphenicol: what we have learned in the last decade. South Med J. 1986;79:1129-1134.
11. Turton JA, Andrews CM, Havard AC, Robinson S, York M, Williams TC, Gibson FM. Haemotoxicity of thiamphenicol in the BALB/c mouse and Wistar Hanover rat. Food Chem Toxicol. 2002;40:1849-1861.
12. Riesbeck K, Bredberg A, Forsgren A. Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob Agents Chemother. 1990;34:167-169.
13. Ibrahim NG, Burke JP, Beattie DS. The sensitivity of rat liver and yeast mitochondrial ribosomes to inhibitors of protein synthesis. J Biol Chem. 1974;249:6806-6811.
14. van den Bogert C, Holtrop M, Melis TE, Roefsema PR, Kroon AM. Different effects of oxytetracycline and doxycycline on mitochondrial protein synthesis in rat liver after long-term treatment. Biochem Pharmacol. 1987;36:1555-1559.
15. Kroon AM, Dontje BH, Holtrop M, van den Bogert C. The mitochondrial genetic system as a target for chemotherapy: tetracyclines as cytostatics. Cancer Lett. 1984;25:33-40.
16. van den Bogert C, Kroon AM. Tissue distribution and effects on mitochondrial protein synthesis of tetracyclines after prolonged continuous intravenous administration to rats. Biochem Pharmacol. 1981;30:1706-1709.
17. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133:1224-1230.
18. Fox SA, Berenyi MR, Straus B. Tetracycline toxicity presenting as a multisystem disease. Mt Sinai J Med. 1976;43:129-135.
19. Finsterer J. Mitochondriopathies. Eur J Neurol. 2004;11:163-186.
20. Cortopassi G, Hutchin T. A molecular and cellular hypothesis for aminoglycosideinduced deafness. Hear Res. 1994;78:27-30.
21. Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet. 1993;4:289-294.
22. Hamasaki K, Rando RR. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry. 1997;36:12323-12328.
23. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1:181-199.
24. Colca JR, McDonald WG, Waldon DJ, et al. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003;278:21972-21979.
25. Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007;26:393-402.
26. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41:2127-2131.
27. Nagiec EE, Wu L, Swaney SM, Chosay JG, Ross DE, Brieland JK, Leach KL. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005;49:3896-3902.
28. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723-2726.
29. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother. 2006;50:1599-1602.
30. Pfister P, Corti N, Hobbie S, Bruell C, Zarivach R, Yonath A, Bottger EC. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G. Proc Natl Acad Sci U S A. 2005;102:5180-5185.
31. Garrabou G, Soriano A, Lopez S, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother. 2007;51:962-967.
32. De Vriese AS, Coster RV, Smet J, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42:1111-1117.
33. Chomyn A. In vivo labeling and analysis of human mitochondrial translation products. Methods Enzymol. 1996;264:197-211.
34. McKee EE, Grier BL, Thompson GS, Leung AC, McCourt JD. Coupling of mitochondrial metabolism and protein synthesis in heart mitochondria. Am J Physiol. 1990;258:E503-E510.
35. McKee EE, Grier BL, Thompson GS, McCourt JD. Isolation and incubation conditions to study heart mitochondrial protein synthesis. Am J Physiol. 1990;258:E492-E502.
36. Chance B, Williams GR. Respiratory enzymes in oxidative phosphorylation: I. Kinetics of oxygen Utilization. J Biol Chem. 1955;217:383-394.
37. Cote C, Boulet D, Poirier J. Expression of the mammalian mitochondrial genome: role for membrane potential in the production of mature translation products. J Biol Chem. 1990;265:7532-7538.
38. O'Brien TW. Properties of human mitochondrial ribosomes. IUBMB Life. 2003;55:505-513.
39. Carson J, Cerda J, Chae JH, Hirano M, Maggiore P. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy. 2007;27:771-774.
40. Palenzuela L, Hahn NM, Nelson RP, Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005;40:E113-E116.